May 8, 2024: On behalf of NCHR, Diana Zuckerman’s testimony at the House Small Business Committee explains that FDA regulations save lives and saves patients’ financial security and do not interfere with innovation in health care.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Comment on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products
April 29, 2024: NCHR backs FDA’s proposed guidance to collect standardized race/ethnicity data in clinical trials, which is crucial for addressing safety and efficacy disparities. We also urge a new category, mandatory implementation, and improved diversity to ensure accurate representation and meaningful efficacy and safety data
Read More »NCHR Comment on Petition Requesting Rulemaking To Mandate Testing and Labeling Regarding Slip Resistance of Flooring, Floor Coatings and Treatments, Floor Cleaning Agents, and Footwear
April 22, 2024: NCHR supports CPSC’s slip resistance testing proposal for flooring but urges more comprehensive safety standards that also evaluate exposure to dangerous chemicals and heavy metals, such as those in rubber flooring.
Read More »Patient, Consumer, and Public Health Coalition Letter to Rep. Pallone in Support of the Ban Water Beads Act (H.R. 6468)
May 1, 2024: We strongly support H.R. 6468 which would expedite the removal of water beads from the market to prevent severe injuries and fatalities due to these products.
Read More »Statement from Dr. Diana Zuckerman Regarding the FDA Final Rule on Regulation of Lab Developed Tests
April 29, 2024: We strongly support today’s FDA’s decision to regulate lab-developed tests. Unfortunately, FDA’s final rules has compromised on the critical issue of grandfathering thousands of tests on the already on the market.
Read More »